StemCells, Inc. (NASDAQ:STEM) has started to show some strength from the last 2 days. With new product launch deadlines in 2010 and being one of the leaders in stem cell research, analyst Stephen M. Dunn has a strong speculative buy target of $2.2 over 12-18 months.
The report (pdf format): link
Google finance link
Current PPS: $1.25
Stem Cells Inc. Website
Wednesday, February 3, 2010
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment